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Abstract
Background: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is
associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries
a lower risk of breast cancer. Limited data suggest differences between progesterone and progestins on
cardiovascular risk factors, including cholesterol and glucose metabolism. Whether this translates to differences in
cardiovascular outcomes is uncertain. We conducted a systematic review and meta-analysis to synthesize the
existing evidence about the effect of progesterone in comparison to synthetic progestins, each in combination
with estrogens, on the risk of breast cancer and cardiovascular events.
Methods: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus through 17
May 2016 for studies that enrolled postmenopausal women using progesterone vs. synthetic progestins and
reported the outcomes of interest. Study selection and data extraction were performed by two independent
reviewers. Meta-analysis was conducted using the random effects model.
Results: We included two cohort studies and one population-based case-control study out of 3410 citations
identified by the search. The included studies enrolled 86,881 postmenopausal women with mean age of 59 years
and follow-up range from 3 to 20 years. The overall risk of bias of the included cohort studies in the meta-analysis
was moderate. There was no data on cardiovascular events. Progesterone was associated with lower breast cancer
risk compared to synthetic progestins when each is given in combination with estrogen, relative risk 0.67; 95 %
confidence interval 0.55–0.81.
Conclusions: Observational studies suggest that in menopausal women, estrogen and progesterone use may be
associated with lower breast cancer risk compared to synthetic progestin.
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Background
Menopausal hormone therapy (MHT) is highly effective
for the treatment of symptoms related to menopause [1].
MHT regimens typically include estrogen and, for women
with an intact uterus, a progestin to protect the endomet-
rium from hyperplasia caused by unopposed estrogen. A
number of US Food and Drug Administration (FDA)-
approved hormone preparations are available for treat-
ment of women with menopausal symptoms [2]. The
biochemistry, metabolism, and both beneficial and harm-
ful effects of the various synthetic progestins differ widely
from native progesterone and from each other [3].
Micronized progesterone is a bioidentical hormone with
a molecular structure identical to that of endogenous
progesterone produced by the ovary. Synthetic progestins
have a different chemical structure from progesterone.
These compounds mimic some of the effects of proges-
terone but may have different actions on progesterone
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receptors [4]. Synthetic progestins may be structurally re-
lated to progesterone (e.g., medroxyprogesterone acetate
(MPA), dydrogesterone) or to testosterone (e.g., levo-
norgestrel, drospirenone) with differing potency and
pharmacokinetics. The physiologic effects of a particu-
lar progestin depend not only on these properties but
also on receptor binding. In addition to binding to pro-
gesterone receptors, these compounds may also have
an affinity for androgen, glucocorticoid, and mineralo-
corticoid receptors [5].
Although some data suggest that MHT increases the
risk of breast cancer [6], the risk of breast cancer may
differ depending on the type of MHT used. For example,
MHT containing conjugated equine estrogens (CEE) and
medroxyprogesterone acetate (MPA) has been associated
with increased risk of breast cancer compared to CEE
alone [7]. Further, breast cancer risk may vary between
regimens containing different progestins, with some syn-
thetic progestins exhibiting greater risk than others [8].
The effects of progesterone have been shown to be
growth-promoting, neutral, or anti-proliferative in breast
cells, whereas in women, synthetic progestins, especially
the combination of CEE and MPA, have been found to
be growth-promoting [9]. In contrast to progestins, pro-
gesterone in combination with estrogen has not been
associated with increased breast cancer [8]. Emerging
evidence suggests that the progesterone receptor acts as
a modulator of estrogen receptor α (ERα) binding and
transcription, blocking estrogen-mediated cell prolifera-
tion. The presence of progesterone receptors in breast
cancer that are positive for ERα is associated with posi-
tive clinical outcomes [10].
Progesterone and synthetic progestins also demonstrate
varied effects on lipids, coagulation factors, glucose, and
insulin and may therefore differentially impact cardiovas-
cular risk, though data are sparse [11].
The PEPI trial previously demonstrated that, when com-
bined with CEE, progesterone, unlike MPA, did not negate
the positive effects of CEE on high-density lipoprotein
cholesterol (HDL-C) [7]. A recent randomized, double-
blind, placebo-controlled trial utilizing 300 mg of pro-
gesterone daily showed no adverse changes in endothe-
lial function, blood pressure, weight, or markers of
inflammation or coagulation. Although HDL-C was de-
creased on treatment, the change was not believed to
be clinically relevant [12]. We conducted a systematic
review and meta-analysis to synthesize the existing evi-
dence about the effect of progesterone compared to
synthetic progestins on the risk of breast cancer and
cardiovascular disease.
Methods
A predefined protocol was developed by experts from
the Endocrine Society to conduct this systematic review.
The protocol included explicit criteria for study selection
and plans for the data extraction and analysis. We
followed the standards set in the Preferred Reporting
Items for Systematic Reviews and Meta-analysis (PRISMA)
[13] statement for reporting this review as shown in
Additional file 1. This systematic review was submit-
ted for PROSPERO registration but it did not meet
registration requirement.
Eligibility criteria
We included comparative/controlled studies that enrolled
women aged 45–59 years who were within 10 years of
menopause and received MHT. The studies had to com-
pare estrogen with progesterone (crystalline progesterone
preparations) with any of the synthetic progestins in com-
bination with estrogen and report outcomes of interest for
a follow-up period ≥6 months. The outcomes of interest
were the risk of breast cancer and cardiovascular disease.
We excluded non-comparative studies, case series, and
non-original papers.
Literature search
The search included the electronic databases of MED-
LINE, MEDLINE in-process and other non-indexed cita-
tions, EMBASE, Cochrane Central Register of Controlled
Trials and Cochrane Database of Systematic Reviews, and
Scopus. We expanded the search to include all languages,
with the latest date of inclusion to be 17 May 2016. The
database search was conducted by an experienced Mayo
Clinic reference librarian. Controlled vocabulary supple-
mented with keywords was used to search for comparative
studies of progesterone vs. synthetic progestins and risk of
breast cancer and cardiac events. A manual search for the
included studies’ bibliographies and previous relevant sys-
tematic review were also conducted. A detailed search
strategy is described in the Additional file 2.
Study selection
Using an online reference management system DistillerSR
(Distiller SR, Evidence Partners Incorporated, Ontario,
Canada), abstracts and titles that resulted from the elec-
tronic search strategy were independently evaluated by
two reviewers for potential eligibility, and the full-text
versions of all potentially eligible studies were obtained.
Two reviewers working independently considered the full-
text reports for eligibility. The level of agreement between
the two reviewers (k level) was 0.7 and 0.8 for abstract
screening and full-text screening, respectively. Disagree-
ments were harmonized by consensus and, if not possible,
by consensus through arbitration by a third reviewer.
Data extraction
Using a standardized, piloted, and web-based form (Distiller
SR; Evidence Partners Inc.), two reviewers independently
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extracted data from each study and later reconciled differ-
ences, if present. Reviewers determined the methodological
quality of studies and collected descriptive, methodological,
and outcome data. We extracted the following variables
from the studies: study characteristics (study design, in-
clusion and exclusion criteria), baseline characteristics, and
patient demographics, and outcome data.
Risk of bias assessment
We used a modified Newcastle-Ottawa Scale (NOS) [14]
to appraise the risk of bias of the observational studies.
The quality of evidence was evaluated using the Grading
of Recommendations Assessment, Development and Evalu-
ation (GRADE) [15] methods.
Data synthesis and statistical analysis
We extracted or calculated the relative risk (RR) of the
outcomes of interest with 95 % confidence interval (CI).
The I2 statistic was used to assess heterogeneity of the
treatment effect among studies for each outcome. I2
value >50 % and p value <0.10 of the Cochrane Q test
suggested substantial heterogeneity that is due to real
differences in study populations, protocols, interventions,
and/or outcomes. Publication bias was not assessed due to
the small number of the studies included. The statistical
analyses using DerSimonian and Laird random effects
model were performed with CMA version 2 (Biostat,
Englewood, New Jersey).
Results
The initial search resulted in 3410 citations. After scre-
ening the abstracts, this was limited to 46 potentially
relevant articles. These were reviewed in full text by two
authors and eventually two cohort studies and one
population-based case-control study were included with
44 being excluded for the reasons shown in Fig. 1. The
included studies enrolled 86,881 women with a mean age
of 59 years and mean follow-up duration of 5 years. None
of the studies evaluated the outcome of cardiovascular
disease. The studies included are summarized in Table 1.
The overall risk of bias of the included cohort studies was
moderate. Samples were somewhat representative in the
two studies with no baseline imbalance, and the studies
were controlled for the most important factors. Table 2
describes the detailed risk of bias assessment of the two
included cohort studies.
Meta-analysis
Based on the meta-analysis of the two included cohort
studies, progesterone was found to be associated with
lower breast cancer risk compared to synthetic proges-
tins in combination with estrogen (RR = 0.67, (95 % CI
Fig. 1 Study selection process. The initial search resulted in 3410 citations. After screening the abstracts, this was limited to 46 potentially relevant
articles. These were reviewed in full text by two authors and eventually two cohort studies and one population-based case-control study were
included with 44 being excluded
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Table 1 Description of included studies







Espie et al. [16] 4949 postmenopausal women were
included in two groups: exposed group,
2693 postmenopausal women who were
receiving MHT or who stopped <5 years,
and unexposed group, 2256 postmenopausal
women who had never received MHT or
who had stopped >5 years.
MHT regimes were estradiol alone (351
postmenopausal women), estradiol + natural
progesterone and estradiol + synthetic
progestins (excluding medroxyprogesterone
acetate and 19-nortestosterone derivatives)
60.6 ± 6.3 for exposed
group, 64.2 ± 8.3 for
unexposed group
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in two groups: MHT never-users with 23,703
postmenopausal women and MHT ever-users
with 56,674 postmenopausal women.
MHT regimes were estrogen alone, estrogen +
progesterone, estrogen + dydrogesterone,
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and other unknown MHT
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55.0 ± 4.8 for MHT
never-users, 52.3 ± 4.1
for MHT ever-users
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0.55–0.81) I2 = 42 % with p value of <0.0001). The quality
of evidence was low due to the observational nature of the
study design, and Fig. 2 shows the results. Sensitivity ana-
lysis was done to exclude postmenopausal women receiv-
ing synthetic progestins other than medroxyprogesterone
acetate. The number of breast cancer events in women
receiving medroxyprogesterone acetate was 29 in 7035
person-years as reported in the study by Fournier et al.
[8]. The sensitivity analysis shows no change in results
(RR = 0.67 (95 % CI 0.76–0.81) with p value of <0.0001).
The effect of combined estradiol and progesterone in
comparison with estradiol and synthetic progestin on
breast cancer incidence showed a RR 0.42 (95 % CI
0.13–1.31) in Espie [16], whereas Fournier [8] showed a
RR 0.68 (95 % CI 0.56–0.82) when comparing postmen-
opausal women who received estrogen and progesterone
to those who received estrogen and synthetic progestin
as shown in Table 3.
The study by Espie [16] reported the route of adminis-
tration of estradiol where 2101 patients (78 %) received
transdermal estradiol and 592 (22 %) received oral estra-
diol. Subgroup analysis was done based on the route of
administration, and no differential effect on the risk of
breast cancer was apparent between oral and transder-
mal routes of administration as shown in Table 4.
We also identified a population-based case-control
study that reported similar results. The study showed no
significant increased risk of breast cancer among women
treated with progesterone in combination with estrogen,
odds ratio (OR) 0.80 (CI 95 % 0.44–1.43). However,
there was a non-significantly increased risk of breast
cancer among users of estrogen with synthetic proges-
tins, OR 1.57 (95 % CI 0.99–2.49) [17].
Discussion
Based on this systematic review and meta-analysis, pro-
gesterone may be associated with lower breast cancer risk
compared to synthetic progestins, when each is given in
combination with estrogen. No studies have been found
reporting on the risk of cardiovascular disease in post-
menopausal woman receiving estrogen with progesterone
vs. those who are receiving estrogen with synthetic pro-
gestins, and no previous systematic reviews have evaluated
this question.
Fig. 2 Random effects model of breast cancer risk in postmenopausal women receiving estrogen with progesterone vs. synthetic progestins. This
figure shows that progesterone was found to be associated with lower breast cancer compared to synthetic progestins in combination
with estrogen












































or files of health insurance
plan. (Pathology reports
were obtained in 96 %
of cases)
Yes
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Progestin is utilized in MHT regimens for women with
an intact uterus to prevent endometrial hyperplasia. Pro-
gestins used for MHT regimens can be administered
orally, transdermally (patch containing norethisterone/
norethindrone), or directly to the endometrium (levo-
norgestrel intrauterine system). While the levonorgestrel
intrauterine system has been shown to be adequate for
endometrial protection [18], it is not currently approved
by the US FDA for this indication.
The potential role of progestins in increasing breast
cancer risk associated with MHT has come under greater
scrutiny after the Women’s Health Initiative trial sug-
gested increased risk of breast cancer with continuous use
of CEE and MPA for greater than 5 years compared with
CEE alone, which showed no increased risk [19]. In fact,
CEE alone was associated with a lower risk of breast
cancer than placebo after 11 years of observation [20].
Both progesterone and synthetic progestins and the
dosing regimen may impact breast cancer risk. In the
E3N cohort study, MHT regimens containing estrogen
and progesterone or dydrogesterone were not associated
with a statistically significant increase in breast cancer
risk. All other progestins were associated with an in-
creased risk, with no difference between various proges-
tins [8]. The results of this meta-analysis (which includes
the E3N study) are consistent with these findings and
show a decreased risk of breast cancer associated with the
use of progesterone compared with a progestin (RR = 0.67
(95 % CI 0.76–0.81)).
Progesterone and synthetic progestins may be admi-
nistered continuously with estrogen or sequentially for
10–14 days per month. Some, but not all, studies compar-
ing these regimens have shown increased risk of breast
cancer with continuous dosing compared to sequential
dosing [21–23]. Randomized clinical trials are needed to
clarify these findings.
Clinical implications
Accumulating evidence suggests that important differ-
ences in risks and benefits exist between various MHT
regimens, making individualization of MHT essential.
Women with an intact uterus require the use of proges-
terone for endometrial protection when using systemic
estrogen therapy for the management of menopausal
symptoms. While an additional study is needed to con-
firm these results, data suggest lower risk of breast
cancer with progesterone and dydrogesterone and do
not support a class effect of progestins on breast cancer
risk [24]. More studies are needed to define a potential
difference in cardiovascular risk between progesterone
and synthetic progestins.
Strengths and limitations
The strength of our review relates to following a predefined
protocol, rigorous database search, and duplicate study
selection and data extraction. The main limitations are the
observational nature of the evidence, which lowers the
confidence in the estimates, and the small number of stud-
ies included. We were unable to ascertain the presence and
impact of publication bias due to the small number of stud-
ies. In terms of the individual studies, the major strength of
the Fournier study [8] was the inclusion of multiple me-
nopausal hormonal therapies: the regular follow-up imple-
mented in the study. It was the first epidemiological study
to provide results indicating that estrogen-progesterone
and estrogen-dydrogesterone combinations may be the
Table 4 The relative risk (95 %) for breast cancer according to the route of administration of estradiol and the type of progestogen
used
Study name Type of MHT Progesterone Synthetic progestins
Espie et al. 2007 [16] Oral estradiol NR 0.81 (0.23–2.85)
Transdermal estradiol 0.46 (0.13–1.62) 1.07 (0.50–2.27)
NR not reported in the study
Table 3 The effect of progesterone vs. synthetic progestins in combination with estrogen on breast cancer incidence
Study Group 1 Incidence of breast
cancer in group 1
Group 2 Incidence of breast




interval (95 % CI)
Espie et al. 2007 [16] Estradiol + progesterone 4/999 Estradiol + synthetic
progestina
12/1272 0.42 0.13–1.31
























aThis study excluded users of medroxyprogesterone acetate and 19-nortestosterone derivatives
bThis is a partial cohort that does not include users of medroxyprogesterone acetate from the analysis
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least harmful MHT in terms of breast cancer risk. However,
the results cannot be translated into firm clinical recom-
mendations. The strength of the Espie study [16] was that
they studied the previous use of progestins prior to meno-
pause. They found that it had no influence on the risk of
breast cancer irrespective of whether or not the women
were subsequently exposed to MHT. One limitation of that
study was that it was influenced by the common practice in
France in which gynecologist avoided prescribing MHT to
high-risk women. Lastly, the results of this review are
largely influenced by a single large study.
Conclusions
Observational studies suggest that in menopausal women
taking estrogen, progesterone use may be associated with
lower breast cancer risk compared to synthetic progestin.
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